Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Midodrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A known ✓ | P35348 | 3/20 | 0.97 |
| ▸ | LMNA | P02545 | 1/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.97 |
| ▸ | TSHR | P16473 | 1/20 | 0.97 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.97 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.97 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.63 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.60 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.60 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.60 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | SCN1A | P35498 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Midodrine SCHEMBL29367411 | 0.99 | ADRA1A (1.00) | ADRA1ALMNACYP1A2TSHRCYP2C19 | |
| (R)-Midodrine SCHEMBL30917926 | 0.99 | ADRA1A (1.00) | ADRA1ALMNACYP1A2TSHRCYP2C19 | |
| (S)-Midodrine SCHEMBL6033144 | 0.99 | ADRA1A (1.00) | ADRA1ALMNACYP1A2TSHRCYP2C19 | |
| Midodrine SCHEMBL131436 | 0.99 | ADRA1A (1.00) | ADRA1ALMNACYP1A2TSHRCYP2C19 | |
| (R)-Midodrine SCHEMBL399213 | 0.99 | ADRA1A (1.00) | ADRA1ALMNACYP1A2TSHRCYP2C19 | |
| Midodrine SCHEMBL41463 | 0.97 | ADRA1A (0.97) | ADRA1ALMNACYP1A2TSHRCYP2C19 | |
| Midodrine SCHEMBL20899416 | 0.97 | ADRA1A (0.97) | ADRA1ALMNACYP1A2TSHRCYP2C19 | |
| Midodrine SCHEMBL29368755 | 0.97 | ADRA1A (0.97) | ADRA1ALMNACYP1A2TSHRCYP2C19 | |
| Midodrine SCHEMBL41464 | 0.96 | ADRA1A (0.95) | ADRA1ALMNACYP1A2TSHRCYP2C19 | |
| Midodrine SCHEMBL20899432 | 0.95 | ADRA1A (0.93) | ADRA1ALMNACYP1A2TSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210322345-A1 | MIDODRINE HYDROCHLORIDE ORAL SOLUTION AND USES THEREOF | Vertica Pharma, LLC | 2021-10-21 | — | — | US | disclosed |
| US-11013702-B2 | Midodrine hydrochloride oral solution and uses thereof | VERTICE PHARMA, LLC (US) | 2021-05-25 | — | — | US | disclosed |
| EP-3582765-B1 | MIDODRINE HYDROCHLORIDE ORAL SOLUTION AND USES THEREOF | VERTICE PHARMA LLC (US) | 2021-04-28 | — | — | EP | disclosed |
| US-20200113851-A1 | MIDODRINE HYDROCHLORIDE ORAL SOLUTION AND USES THEREOF | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2020-04-16 | — | — | US | disclosed |
| WO-2019075127-A1 | MIDODRINE HYDROCHLORIDE ORAL SOLUTION AND USES THEREOF | VERTICE PHARMA, LLC (US) | 2019-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210322345-A1 | MIDODRINE HYDROCHLORIDE ORAL SOLUTION AND USES THEREOF | MTX1, MDK, MTX2 | ADRA1A 155/4885LMNA 3564/4885CYP1A2 439/4885 |
| US-11013702-B2 | Midodrine hydrochloride oral solution and uses thereof | MTX1, MDK, MTX2 | ADRA1A 155/4885LMNA 3564/4885CYP1A2 439/4885 |
| US-20200113851-A1 | MIDODRINE HYDROCHLORIDE ORAL SOLUTION AND USES THEREOF | MTX1, MDK, MTX2 | ADRA1A 155/4885LMNA 3564/4885CYP1A2 439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.